Redmile Group, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001425738
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 63 positions · Total reported value $1.70B · Top-10 concentration 44.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 69.2% · 4 new · 23 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +21.6% · vs SPY +6.8% · Prev Value $1.51B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2024 13F filing, Redmile Group, LLC disclosed 63 equity positions with a combined reported value of $1.70B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 44.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were KRYS ($147.49M), NRIX ($96.19M), FOLD ($88.07M). By sector, the heaviest allocations are Health Care 82.3%, Materials 0.0%. Versus the prior quarter, allocation shifted toward Other (+1.3pp) and away from Health Care (-1.3pp).
Versus the prior quarter, Redmile Group, LLC opened 4 new positions, trimmed 23 and fully exited 0, a turnover rate of 69.2% of positions. The portfolio's overlap with the prior quarter was 88% of names.
The largest new positions opened in Q3 2024 were BNTX ($18.34M), ORKA ($10.09M), ATXS ($3.42M).
Of the 4 positions fully exited versus the prior quarter, the largest were BPMC ($10.17M), TRDA ($7.99M), LAB ($728.59K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
- BNTX BIONTECH SE · $18.34M
- ORKA ORUKA THERAPEUTICS INC · $10.09M
- ATXS ASTRIA THERAPEUTICS INC · $3.42M
- PEN PENUMBRA INC · $2.69M
Insider Transactions (Form 4)
Latest Redmile Group, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-06 | Buy | Attovia Therapeutics, Inc. | 400,000 | $17.00 | SEC filing |
| 2026-08-06 | Buy | Attovia Therapeutics, Inc. | 200,000 | $17.00 | SEC filing |
| 2026-08-06 | Conversion | Attovia Therapeutics, Inc. | 782,854 | — | SEC filing |
| 2026-07-22 | Tax payment | Atara Biotherapeutics, Inc. | 60 | — | SEC filing |
| 2026-07-22 | Opt exercise | Atara Biotherapeutics, Inc. | 195,211 | — | SEC filing |
| 2026-04-20 | J | FATE THERAPEUTICS INC | 8,977,624 | — | SEC filing |
Fund Profile
Redmile Group, LLC, based in Larkspur, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $1.49B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: LARKSPUR, CA, United States
- SEC registration: 801-67747 (status: Approved), registered 2007-04-19
- Regulatory AUM (Form ADV): $4.70B as of 2026-08-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 20 private funds, of which 10 hedge funds
- Website: redmilegroup.com
Portfolio Structure
- 39 positions · $1.49B reported value (Q2 2026)
- Top 10 holdings = 73.5% of reported value
- Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 15.9%
- Average position size: $38.19M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 5 added, 23 reduced
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
810.25K | $147.49M | 8.69% | Reduce | |
| 2 |
|
4.28M | $96.19M | 5.67% | Reduce | |
| 3 |
|
8.25M | $88.07M | 5.19% | Reduce | |
| 4 |
|
4.89M | $71.49M | 4.21% | Hold | |
| 5 |
|
1.39M | $65.94M | 3.88% | Reduce | |
| 6 |
|
5.10M | $64.03M | 3.77% | Reduce | |
| 7 |
|
4.71M | $57.93M | 3.41% | Hold | |
| 8 |
|
4.78M | $52.40M | 3.09% | Reduce | |
| 9 |
|
1.03M | $51.68M | 3.04% | Reduce | |
| 10 |
|
4.89M | $51.33M | 3.02% | Add | |
| 11 |
|
3.07M | $50.82M | 2.99% | Hold | |
| 12 |
|
15.67M | $49.36M | 2.91% | Add | |
| 13 |
|
4.48M | $48.43M | 2.85% | Reduce | |
| 14 |
|
13.17M | $46.09M | 2.71% | Hold | |
| 15 |
|
875.04K | $45.97M | 2.71% | Reduce | |
| 16 |
|
5.24M | $41.96M | 2.47% | Reduce | |
| 17 |
|
964.35K | $40.46M | 2.38% | Reduce | |
| 18 |
|
1.39M | $39.81M | 2.35% | Reduce | |
| 19 |
|
1.61M | $39.47M | 2.33% | Reduce | |
| 20 |
|
16.38M | $38.49M | 2.27% | Hold | |
| 21 |
|
6.43M | $38.05M | 2.24% | Hold | |
| 22 |
|
595.57K | $36.07M | 2.12% | Hold | |
| 23 |
|
3.20M | $35.84M | 2.11% | Hold | |
| 24 |
|
1.90M | $34.53M | 2.03% | Reduce | |
| 25 |
|
552.51K | $32.08M | 1.89% | Hold | |
| 26 |
|
8.25M | $31.53M | 1.86% | Hold | |
| 27 |
|
330.87K | $27.73M | 1.63% | Reduce | |
| 28 |
|
657.17K | $22.34M | 1.32% | Reduce | |
| 29 |
|
681.15K | $21.58M | 1.27% | Reduce | |
| 30 |
|
5.62M | $19.60M | 1.16% | Hold | |
| 31 |
|
154.46K | $18.34M | 1.08% | New | |
| 32 |
|
642.23K | $18.31M | 1.08% | Reduce | |
| 33 |
|
1.26M | $13.64M | 0.80% | Add | |
| 34 |
|
26.70K | $13.12M | 0.77% | Reduce | |
| 35 |
|
32.74K | $11.83M | 0.70% | Reduce | |
| 36 |
|
1.57M | $11.62M | 0.68% | Reduce | |
| 37 |
|
1.66M | $11.44M | 0.67% | Reduce | |
| 38 |
|
261.80K | $11.33M | 0.67% | Add | |
| 39 |
|
411.73K | $10.09M | 0.59% | New | |
| 40 |
|
2.07M | $8.03M | 0.47% | Hold | |
| 41 |
|
3.84M | $6.98M | 0.41% | Reduce | |
| 42 |
|
3.03M | $6.94M | 0.41% | Hold | |
| 43 |
|
1.38M | $6.70M | 0.39% | Reduce | |
| 44 |
|
1.94M | $6.68M | 0.39% | Hold | |
| 45 |
|
1.69M | $6.40M | 0.38% | Reduce | |
| 46 |
|
97.12K | $5.13M | 0.30% | Reduce | |
| 47 |
|
2.11M | $4.59M | 0.27% | Reduce | |
| 48 |
|
2.11M | $4.30M | 0.25% | Hold | |
| 49 |
|
452.27K | $3.68M | 0.22% | Hold | |
| 50 |
|
1.02M | $3.55M | 0.21% | Reduce | |
FAQ
What did Redmile Group, LLC buy in 2024-Q3?
In its 2024-Q3 13F filing, Redmile Group, LLC reported 63 equity positions worth $1.70B in aggregate; its largest disclosed positions were KRYS ($147.49M), NRIX ($96.19M), FOLD ($88.07M).
How large is Redmile Group, LLC's portfolio?
Redmile Group, LLC reported $1.70B of long equity holdings across 63 positions as of 2024-Q3. Top-10 holdings account for 44.0% of reported value.
What is Redmile Group, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.